Pfizer and BioNTech said a study found that an improved vaccine against the Omicron variant produced a significantly larger immune response than the company’s existing vaccine. The modified booster shot for Omicron resulted in study volunteers having neutralizing antibody levels 13.5 to 19.6 times higher than the current vaccine one month after dosing, depending on the dose. A booster shot against Omicron as well as the original strain increased neutralizing antibody levels by a factor of 9.1 to 10.9, depending on the dose. Both adjusted vaccine candidates were well tolerated by subjects in the study. The study did not measure whether the improved vaccine reduces the risk of Covid-19 infection, and to what extent.
This article is reprinted from: https://www.solidot.org/story?sid=71946
This site is for inclusion only, and the copyright belongs to the original author.